Back
IL-12-and IL-23 in health and disease.
Journal article

IL-12-and IL-23 in health and disease.

  • Croxford AL Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland. Electronic address: andrewlewis.croxford@uzh.ch.
  • Kulig P Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
  • Becher B Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
  • 2014-08-19
Published in:
  • Cytokine & growth factor reviews. - 2014
Autoimmunity
Cytokines
IL-12 family
Inflammation
Treatment
Animals
Arthritis, Rheumatoid
Humans
Inflammation
Inflammatory Bowel Diseases
Interleukin-12
Interleukin-12 Subunit p40
Interleukin-17
Interleukin-23
Mice
Neoplasms
Psoriasis
Th1 Cells
Th17 Cells
English Interleukin (IL)-12 and IL-23 play important roles in the development of experimental autoimmune disease models and numerous afflictions affecting humans. Preclinical data over the last 20 years combined with successful clinical trials has identified a clear relationship between IL-12, IL-23 and the generation of pathogenic T helper cells capable of orchestrating tissue inflammation. Observations made in the clinic have shown that IL-12p40, a common subunit shared by IL-12 and IL-23, is critical to pathologies associated with psoriasis, inflammatory bowel disease (IBD) and tumor growth. These advancements have set in motion the development of a number of potential therapeutics aimed at manipulating IL-12/23 signaling pathways in both mice and humans. This review will discuss a brief history of the understanding and expansion of the IL-12 cytokine family, some difficulties associated with preclinical data interpretation and finally the medicinal interventions that have been developed to combat IL-12/23-driven autoimmune disorders.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/96802
Statistics
Document views: 57 File downloads: